Risk of cervical intraepithelial neoplasia grade 3 or more diagnoses for human papillomavirus16/18-positive women by cytology and co-infection status

[1] de Sanjose S(2010)Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 1048-1056

[2] Quint W(2020)2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors J Low Genit Tract Dis 24 102-131

[3] Alemany L(2012)The ATHENA human papillomavirus study: design, methods, and baseline results Am J Obstet Gynecol 206 46.e1-46.e11

[4] Perkins R(2021)Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in china: a multicenter, open-label Random Clin Trial JAMA Oncol 7 263-270

[5] Guido R(2020)Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin 70 321-346

[6] Castle P(2019)Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: a large population-based study Gynecol Oncol 155 436-443

[7] Wright T(2021)Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study J Infect 82 75-83

[8] Stoler M(2010)HPV genotype distribution according to severity of cervical neoplasia Gynecol Oncol 118 29-34

[9] Behrens C(2009)Cervical infections by multiple human papillomavirus (HPV) genotypes: prevalence and impact on the risk of precancerous epithelial lesions J Med Virol 81 703-712

[10] Apple R(2014)Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31–65 Gynecol Oncol 133 405-408

[1] de Sanjose S(2010)Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 1048-1056

[2] Quint W(2020)2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors J Low Genit Tract Dis 24 102-131

[3] Alemany L(2012)The ATHENA human papillomavirus study: design, methods, and baseline results Am J Obstet Gynecol 206 46.e1-46.e11

[4] Perkins R(2021)Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in china: a multicenter, open-label Random Clin Trial JAMA Oncol 7 263-270

[5] Guido R(2020)Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin 70 321-346

[6] Castle P(2019)Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: a large population-based study Gynecol Oncol 155 436-443

[7] Wright T(2021)Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study J Infect 82 75-83

[8] Stoler M(2010)HPV genotype distribution according to severity of cervical neoplasia Gynecol Oncol 118 29-34

[9] Behrens C(2009)Cervical infections by multiple human papillomavirus (HPV) genotypes: prevalence and impact on the risk of precancerous epithelial lesions J Med Virol 81 703-712

[10] Apple R(2014)Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31–65 Gynecol Oncol 133 405-408